Bivatracin Spray Topical Antibacterial

Bivatracin is indicated for:


  • Pyodermia epidermal (impetigo group).
  • Epidermocutaneous pyodermia (folliculitis)- primarily to prevent spread of infection.
  • Superinfections of surface wounds and burns.
  • Bacterial dermatopathies (ecthyma gangrenosum).
  • Prevention of pyococcal superinfections in case of increased risk of their occurrence (herpes simplex, herpes zoster, bites of insects).


  • Inflammation of the external ear canal.
  • For prophylaxis, Bivatracin is also used in surgery and otorhinolaryngology.

Dosage And Administration

  • Shake the aerosol container vigorously and spray the powder to the affected area once or several times daily from a distance of 20 to 25cm.
  • Do not incline to an angle greater than 45°.
  • After use clean the valve by turning the aerosol container upside down and blow the valve by short pressing.
  • Occasional agglomeration of powder in the valve can be cleaned with a hypodermic needle no (15-17).
  • Apply sparingly.
  • Application of Bivatracin Spray should be limited to a maximum of one cans per day for not more than seven days.
  • Apply the powder spray to the affected area as a thin layer once or several times daily.

Over Dosage

Systemic toxic effects (nephrotoxicity and ototoxicity) are unlikely to occur and may appear only after prolonged use of large doses over wide areas of the affected skin.


Each 150ml of Bivatracin aerosol powder contains: 165000 IU Neomycin in the form of Neomycin Sulphate, 12500 IU Bacitracin in the form of Bacitracin Zinc, 150ml Aerosol Hydrocarbon to.


A wide range of antibacterial action is provided by the overlapping spectra of Neomycin and Bacitracin. Bivatracin is used for topical treatment of most infections caused by gram-positive and gram-negative bacteria, it is practically not absorbed, therefore it has no systemic action.


  • Hypersensitivity to Neomycin, Bacitracin and other ingredients of this combination.
  • Perforation of the eardrum at local application into ear canal.


Systemic absorption can occur following application over large areas (> 20%), on wounds, burns or ulcerations. Since systemic absorption can occur through the skin, Bivatracin should be used cautiously in patients with renal insufficiency as it may increase the hazard of nephrotoxicity and ototoxicity.

Bivatracin should be discontinued if any signs of skin irritation or hypersensitivity occur.

Special warnings

Pregnancy and lactation

  • Bivatracin should be used during pregnancy and lactation only if clearly indicated and should not be used over wide areas and for prolonged periods to prevent the risk of systemic absorption associated with topical use.
  • Aerosol container is under pressure, it contains a gas propellant.
  • Do not perforate or burn, even when empty.

Bivatracin should be kept out of reach of children. For external application only.

Drug interactions

None reported

Side Effects

Hypersensitivity reaction may occur, local skin irritation, swelling, itching, urticaria, contact dermatitis, super Infection have been reported.

Other Information


  •  Store Bivatracin Spray at a temperature below 25°C.
  • Keep the medicine from freezing.
  • Keep the container away from direct heat sources.
  • Keep out of reach of children.


Box containing a can spray of 150 ml aerosol powder and inner leaflet.

بيفاتراسين سبراى
بيفاتراسين سبراى
أسم الدواء بيفاتراسين سبراى
المكون النشط نيوميسين + باسيتراسين
دواعى الاستعمال مضاد حيوى
حجم العبوة 150 مل
الشركة اكديما

بيفاتراسين سبراى – النشرة الداخلية.